@article{JGO18443,
author = {Whitney L. Guerrero and Gitonga Munene and Paxton V. Dickson and Dina Darby and Andrew M. Davidoff and Michael G. Martin and Evan S. Glazer and David Shibata and Jeremiah L. Deneve},
title = {Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {2},
year = {2018},
keywords = {},
abstract = {Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program.
Methods: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/ HIPEC with clinicopathologic data described.
Results: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11–73 years). Primary pathology included: appendix (42%, n=21), ovary (18%, n=9), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1–39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6–35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities.
Conclusions: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/18443}
}